BIO

Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

Retrieved on: 
金曜日, 5月 31, 2024
ChromeOS, WAKE, US FDA, FDA, Drug development, EMA, CNS, MHRA, BIO, MOU, Pharmaceutical industry

Julius Clinical, established in 2008 and headquartered in Zeist, The Netherlands, specializes in CNS, cardiometabolic, and rare diseases.

Key Points: 
  • Julius Clinical, established in 2008 and headquartered in Zeist, The Netherlands, specializes in CNS, cardiometabolic, and rare diseases.
  • The non-exclusive MOU between Avance Clinical and Julius Clinical offers a streamlined global solution for biotech clients.
  • Avance Clinical CEO, Yvonne Lungershausen noted that Avance Clinical has expanded globally establishing operations now in Europe, Australia, New Zealand, Asia and North America.
  • "Julius Clinical are an ideal partner for Avance Clinical because they lead with scientific expertise and can support our biotech clients with specialist CNS, cardiometabolic and rare diseases clinical operations and site relationships in Europe," Lungershausen said.

ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING

Retrieved on: 
木曜日, 5月 30, 2024
Therapy, Ecosystem, Biotechnology, OTCQB, BIO

AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego.

Key Points: 
  • AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego.
  • The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe.

ORYZON to Provide Corporate Progress Updates at Several Events in June

Retrieved on: 
木曜日, 5月 30, 2024
Patient, FLT3, Congress, ALS, Karolinska Institute, EHA, San Diego Convention Center, BIO, Hospital, Genomics, European Hematology Association, Mutation, Principal

MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in June.

Key Points: 
  • MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in June.
  • Oryzon will attend BIO International 2024, which will be held at the San Diego Convention Center in San Diego (USA) on June 3-6, where the company will hold one-on-one meetings with pharmaceutical companies and global investors.
  • Click on the link for more info about EHA2024
    Oryzon will attend the European Network to Cure ALS (ENCALS) 2024 meeting, which will take place at the Karolinska Institutet in Stockholm (Sweden) on June 17-20.
  • Click on the link for more info about ENCALS 2024

Fujifilm to Showcase Innovation, Expertise and Breadth of Life Sciences Offerings at BIO 24

Retrieved on: 
木曜日, 5月 30, 2024
Fujifilm, Drug development, Fujifilm Diosynth Biotechnologies, Cell, San Diego Convention Center, Liposome, BIO, Exponential, Biotechnology, Wako, Nucleic acid

BIO 24 is the largest event in biotechnology, with over 20,000 industry members expected to join from around the globe and across the biotech ecosystem.

Key Points: 
  • BIO 24 is the largest event in biotechnology, with over 20,000 industry members expected to join from around the globe and across the biotech ecosystem.
  • “Fujifilm is excited to join the premier biotech industry event to showcase our talent and experience in life sciences as we meet with innovators and demonstrate how our life science solutions can offer current and future customers support in advancing therapies,” says Toshihisa Iida, corporate vice president, general manager, Life Sciences Strategy Headquarters, FUJIFILM Corporation.
  • With its combined expertise, Fujifilm offers customers end-to-end solutions in life sciences.
  • Fujifilm businesses joining BIO 24 include FUJIFILM Diosynth Biotechnologies, FUJIFILM Cellular Dynamics, FUJIFILM Irvine Scientific, FUJIFILM Toyama Chemical, and FUJIFILM Wako Pure Chemical Corporation.

Humanetics Corporation to Present at the BIO International Convention in San Diego

Retrieved on: 
金曜日, 5月 31, 2024
Health, Radiology, Pharmaceutical, Clinical Trials, Oncology, Private law, Patient, Cancer, Biotechnology Innovation Organization, BIO

Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week.

Key Points: 
  • Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week.
  • This convention, known for its global reach and influence, provides a platform for industry leaders to showcase their innovations.
  • Ronald J. Zenk, Chief Executive Officer, will present this information on Monday, June 3, 2024 (1:30 pm Company Presentation Theatre 3).

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Retrieved on: 
金曜日, 5月 31, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Netherton, Netherton syndrome, EGFR, San Diego Convention Center, Toxicity, BIO

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
  • The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center.
  • The corporate update will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.
  • Azitra’s presentation details are as follows:
    To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact [email protected]

AI Proteins to Attend BIO 2024; Company Provides Update on Technology Platform and Programs

Retrieved on: 
木曜日, 5月 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Diabetes, Patient, Hope, Bone marrow, Protein, Obesity, Molecular biology, De novo, IND, DSM-IV codes, Psoriasis, AI, Inflammation, Cancer, TNFR1, Systemic inflammation, BIO, Crohn's disease, Weight loss, Therapy, Antibody, Lead, Rheumatoid arthritis, Engagers, Fine chemical

Unlike antibodies, these proteins can be engineered to achieve higher specificity, valency, stability, and efficacy, opening new avenues for therapeutic interventions.

Key Points: 
  • Unlike antibodies, these proteins can be engineered to achieve higher specificity, valency, stability, and efficacy, opening new avenues for therapeutic interventions.
  • We have robust business development activities underway with pharmaceutical partners to further leverage our unique technology platform and programs.
  • Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins.
  • Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.

Shaperon & Hudson to Participate in the 2024 Bio International Convention

Retrieved on: 
木曜日, 5月 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, MASH, Veterinary medicine, Technology transfer, Obesity, AACR, Therapy, Animal, Atopic dermatitis, BIO, Ulcerative colitis, Biotechnology Innovation Organization

Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq: 378800) and Hudson Therapeutics, Inc. which is the US Subsidiary of Shaperon will attend the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California to explore partnering opportunities.

Key Points: 
  • Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq: 378800) and Hudson Therapeutics, Inc. which is the US Subsidiary of Shaperon will attend the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California to explore partnering opportunities.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering, attracting global biotechnology and biopharmaceutical leaders.
  • The event offers networking, programming, and partnering and investor opportunities.
  • BIO’s One-on-One Partnering™ facilitates meetings with senior biotech executives, business development leaders, and investors, with over 57,000 partnering meetings held at the last in-person BIO convention.

Enveric Biosciences to Participate in BIO International Convention 2024

Retrieved on: 
木曜日, 5月 30, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Therapy, Depression, Addiction, Anxiety, BIO, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
  • During the conference, Enveric's management team plans to host meetings with potential investment and development partners to discuss and explore potential collaborations for the Company’s various promising drug candidates.
  • “We look forward to meeting with our colleagues across the industry at BIO as we continue to receive significant interest from potential strategic partners in the pharmaceutical industry for various assets produced by our drug discovery engine,” said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric.

Apollomics Announces Presentation at the 2024 BIO International Convention

Retrieved on: 
水曜日, 5月 29, 2024
APLM, BIO

FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Key Points: 
  • FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
  • BIO International Convention (June 3-6, 2024)
    Management will be available for one-on-one meetings with registered attendees.
  • To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact [email protected] .